Products - Blood conditions | Topic

Showing 26 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Suspected sepsis in people aged 16 or over: recognition, assessment and early management (NG253)
Product type:
Guidance
Programme:
NICE guideline
Published:
19 November 2025
Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early management (NG255)
Product type:
Guidance
Programme:
NICE guideline
Published:
19 November 2025
Suspected sepsis in under 16s: recognition, diagnosis and early management (NG254)
Product type:
Guidance
Programme:
NICE guideline
Published:
19 November 2025
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over (TA1101)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 October 2025
Suspected sepsis in over 16s (QS213)
Product type:
Quality standard
Published:
19 November 2025
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 June 2026
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
19 August 2026
Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
3 September 2026
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 November 2026
Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors [ID5099]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ferric citrate for managing iron and serum phosphorus levels in anaemia associated with chronic kidney disease [TSID12221]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avexitide for treating hypoglycaemia after bariatric surgery [TSID12233]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lanadelumab for preventing recurrent attacks of hereditary angioedema in people 2 years and over [TSID12298]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Concizumab for treating haemophilia A or B in people 12 years and over with inhibitors [ID6665]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Etavopivat for treating sickle cell disease in people 12 years and over [TSID12320]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Luspatercept for Anaemia due to myelodysplastic syndromes [TSID12310]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Luspatercept for treating anaemia caused by myelofibrosis [TSID12309]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Peginterferon alfa-2a for treating polycythaemia vera or essential thrombocythaemia [TSID12325]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Blood conditions Products

Filter

Product type

Guidance programme

Status

New and updated
1 selected

Showing 26 products

Suspected sepsis in people aged 16 or over: recognition, assessment and early management (NG253)

Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early management (NG255)

Suspected sepsis in under 16s: recognition, diagnosis and early management (NG254)

Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over (TA1101)

Suspected sepsis in over 16s (QS213)

Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]

Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors [ID5099]

Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]

Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]

Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]

Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400

Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]

Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]

Ferric citrate for managing iron and serum phosphorus levels in anaemia associated with chronic kidney disease [TSID12221]

Avexitide for treating hypoglycaemia after bariatric surgery [TSID12233]

Lanadelumab for preventing recurrent attacks of hereditary angioedema in people 2 years and over [TSID12298]

Concizumab for treating haemophilia A or B in people 12 years and over with inhibitors [ID6665]

Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]

Etavopivat for treating sickle cell disease in people 12 years and over [TSID12320]

Luspatercept for Anaemia due to myelodysplastic syndromes [TSID12310]

Luspatercept for treating anaemia caused by myelofibrosis [TSID12309]

Peginterferon alfa-2a for treating polycythaemia vera or essential thrombocythaemia [TSID12325]

Blood conditions Products

Filter

Product type

Guidance programme

Status

New and updated1 selected

Showing 26 products

New and updated
1 selected